FDA approvedMetabolic & fat loss

Semaglutide

Ozempic, Wegovy, Rybelsus

REC PPT-SEMAGLUTIDE // REV 2026-10-04 // assessment changes are logged, never silent

GLP-1 agonist. Approved, trial-backed, and genuinely effective for weight and glycaemic control.

What it is

A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, approved under brand names including Ozempic and Wegovy.

What it does

Slows gastric emptying, increases satiety signalling and improves glycaemic control — producing substantial weight loss in trials.

Does it work?

Among the most rigorously tested compounds here, with large randomised trials and regulatory approval in many markets including Saudi Arabia. Side effects are well documented. This is a prescription medicine and should be obtained and supervised through a licensed physician.

Claims vs data

Each marketing claim, tagged by what the evidence actually supports.

Produces clinically meaningful weight loss	supported
Improves glycaemic control in type 2 diabetes	supported
Free of side effects	overreach

Reference figures

Quoted from published reference material. These are not Peptuity recommendations.

Vial3 mg

Diluent2 ml

Listed dose250 mcg

Units / 1 ml17

FormulaC187H291N45O59

Mol. weight4114 g/mol

molecular data — PubChem CID 56843331

Open in the calculator — prefilled →

The evidence, counted

Live counts from Europe PMC and ClinicalTrials.gov.

Publications 17,774

Randomised trials 640

Clinical trials 434

Registered studies 650

17,774 publications indexed, including 640 randomised controlled trials. 650 interventional studies registered. This is a well-tested compound.

SRC // EUROPE PMC + CTGOV // "Semaglutide" // FETCHED 2026-10-04 // 17,774 RECORDS

Most-cited literature

[01] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lin · N Engl J Med 2016 · 5002 citations · DOI 10.1056/nejmoa1607141
[02] Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker · Circulation 2023 · 4027 citations · DOI 10.1161/cir.0000000000001123
[03] Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I · N Engl J Med 2021 · 3862 citations · DOI 10.1056/nejmoa2032183
[04] Mechanisms of NAFLD development and therapeutic strategies
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. · Nat Med 2018 · 3386 citations · DOI 10.1038/s41591-018-0104-9

Regulatory status

Formal, dated regulatory actions.

WADA — Prohibited List 2026

Not on the WADA Prohibited List

source →

Common questions

Is semaglutide available in Saudi Arabia?

Yes — it is an SFDA-registered prescription medicine under its brand names. It is dispensed through pharmacies with a prescription, not bought as a research compound.

How is grey-market semaglutide different?

Vialled research-grade product has no regulatory oversight of identity, purity or dose accuracy. The trial evidence applies to the approved pharmaceutical, not to unverified vials.

Do you advise on dosing?

No. It is a prescription medicine; dosing and titration belong with the prescribing physician.

Related compounds

FDA approved